While many studies have demonstrated delayed tumor progression through the inhibition of the VEGF-A and HIF-1a pathway, randomized, placebo-controlled, phase III trials of BEV have not shown an overall survival benefit [90,112,113]. The gene discussed is VEGFA; the disease is neoplasm.